WebAug 5, 2024 · EX-10.1 - Master Services Agreement, between Synaptogenix, Inc. and Worldwide Clinical Trials, Inc., dated as of February 7, 2024 and Work Order, dated May … WebSynaptogenix, Inc. operates as a biopharmaceutical company. The Company focuses on developing a product platform for the treatment of Alzheimer's disease, as well as …
Synaptogenix, Inc. General Corporate Statement (Form8)
WebFind the latest Synaptogenix, Inc. (SNPX) stock quote, history, news and other vital information to help you with your stock trading and investing. WebApr 6, 2024 · A high-level overview of Synaptogenix, Inc. (SNPX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. goodman control board pcbbf132
Synaptogenix - Overview, News & Competitors ZoomInfo.com
WebFeb 23, 2024 · About Synaptogenix, Inc. Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. WebSynaptogenix started at buy with $14 stock price target at Maxim Group. Apr. 12, 2024 at 8:15 a.m. ET by Tomi Kilgore. Other News. WebFeb 10, 2024 · Haywood George Weaver has filed a 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 485,000 shares of Synaptogenix, Inc. (Top holders of Synaptogenix, Inc. sourced from 13F and NPORT filings include: • Ikarian Capital, LLC • Cannell Peter B & Co Inc • Diametric Capital, LP • goodman control board pcbbf110